GPT and metabolic dysfunction-associated steatohepatitis: In a 54-week phase 2b study, cotadutide led to positive changes in body weight, serum ALT levels, and scores of hepatic steatosis and fibrosis (NFS and FIB-4) in patients with NASH and T2DM [110].